Robert J. Motzer

Robert J. Motzer, MD is the Jack and Dorothy Byrne Chair in Clinical Oncology and Attending Physician in the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC). With a career spanning more than three decades, he is one of the most influential figures in the history of renal cell carcinoma (RCC) research, having shaped virtually every era of advanced RCC treatment from cytokine therapy through targeted therapy to the current immunotherapy era. His body of work encompasses landmark clinical trials, prognostic modeling, and translational discovery that have fundamentally defined how kidney cancer is understood and treated globally. Dr. Motzer is the architect of the MSKCC Prognostic Model (also called the Motzer criteria), a foundational risk stratification tool for metastatic RCC that identifies favorable-, intermediate-, and poor-risk patients based on clinical factors and has been used as the basis for stratification in virtually every major RCC trial since its publication. He was also the principal investigator of the pivotal phase III trial establishing sunitinib as the first-line standard in metastatic RCC, replacing interferon alfa. Most recently, he led CheckMate 214, the landmark phase III trial demonstrating that the combination of nivolumab plus ipilimumab produced superior long-term overall survival versus sunitinib in intermediate- and poor-risk treatment-naive advanced RCC, fundamentally establishing dual checkpoint blockade as a first-line standard for this population. Dr. Motzer has also led CheckMate 9ER and other major trials evaluating nivolumab plus cabozantinib and other IO-TKI combinations, cementing MSKCC's preeminence in RCC clinical research. He has authored more than 400 peer-reviewed publications and is consistently recognized among the most cited researchers in oncology globally. His contributions span biology, trial design, and clinical practice standards that have improved survival for hundreds of thousands of patients worldwide.